Cessation of withdrawal syndrome in patients with alcohol dependence using the drug Liveria® IC

November 6, 2017
Specialities :

60 patients with the diagnosis «Mental and behavioral disorders due to alcohol use, uncomplicated withdrawal syndrome» took part in the study. The research was conducted on admission, on 10th and 30th day of treatment. Patients of the main group (n=30) received basic treatment in combination with Liveria® IC 500 mg twice a day, control (n=30) — only basic treatment. To assess the effectiveness of the treatment the biochemical blood testing was performed (total bilirubin, direct bilirubin, indirect bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase), ultrasound examination of the liver. There were also used Lusher’s color selection method and self-evaluation technique (well-being, activity, mood). Detoxifying effect of the drug Liveria® IC manifested in the repression of somatic and vegetative symptoms and rapid disappearance of mental discomfort. Psychopathological manifestations, such as alcohol attraction, anxiety, tension, depressive component, feelings of guilt, deterioration of mental activity, were performed in 3–4 days earlier than in the control group. The main criteria of the hepatotropic activity of the drug was its ability to reduce the activity of liver enzymes. At the 30th day of treatment the activity of liver transaminases has been normalized, and in the main group the results exceeded the control group, which proves the hepatoprotective effect of the Liveria® IC. The addition the drug Liveria® IC to the therapy reduced the treatment time of the withdrawal syndrome and has an indirect positive effect on the mental sphere of patients.

V.V. Yariy, Yu.Ya. Smirnova, A.I. Khmelenko, G.T. Kalandiya

Key words: Key words: alcohol dependence, alcohol consumption, withdrawal syndrome, Liveria® IC.